Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes and heart or kidney disease.

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Karen Coe, 59, who has type 2 diabetes, says she was prescribed a GLP-1 medication to help her lose weight and get her ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

THE ‘King Kong’ of fat jabs could help dieters keep weight off for three years, a study has revealed. Italian scientists ...

One popular and affordable supplement that has shown some promise in helping with weight loss is berberine. In fact, some ...

Berberine is a powder made from different plants. It has many benefits, including improving blood sugar levels, reducing ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...